Want to see PLX full AI Analyst Report?
PLX Stock Chart & Stats
$2.61
$0.06(2.53%)
At close: 4:00 PM EDT
$2.61
$0.06(2.53%)
Day’s Range― - ―
52-Week Range$1.52 - $3.19
Previous CloseN/A
Volume129.84K
Average Volume (3M)759.42K
Market Cap
$215.13M
Enterprise Value$160.20
Total Cash (Recent Filing)$27.42M
Total Debt (Recent Filing)$9.21M
Price to Earnings (P/E)11.1
Beta0.73
Next Earnings
Nov 16, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding80,571,640
10 Day Avg. Volume731,231
30 Day Avg. Volume759,418
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.93
Price to Sales (P/S)2.68
P/FCF Ratio-10.37
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.22
Revenue Forecast (FY)$79.79M
Bulls Say, Bears Say
Bulls Say
Elfabrio Commercial ExpansionGrowing Elfabrio sales alongside additional geographic and dosing approvals can broaden the product’s commercial reach and improve recurring product-related economics. The regulatory progress supports deeper penetration of the Fabry market and strengthens Protalix’s established partnered product franchise over the coming quarters.
Improved Profitability And LiquidityPositive earnings, strong operating margins, and a debt-free balance sheet give Protalix greater capacity to fund operations and advance its pipeline internally. Current liquidity also reduces financing pressure, while improved profitability provides a stronger base for sustaining investment through future development cycles.
Integrated Biologics PlatformA proprietary expression platform spanning development and manufacturing gives Protalix an integrated foundation for producing recombinant biologics, particularly in rare diseases. This capability can support repeated product development and partnered supply opportunities rather than relying on a single commercial asset.
Bears Say
Partner Concentration And Sales VolatilityReliance on a major commercialization partner and uneven purchasing patterns can make reported revenue difficult to forecast from quarter to quarter. This volatility may obscure underlying product demand, complicate planning, and increase dependence on partner inventory decisions for near-term operating performance.
Dependence On A Non-recurring MilestoneThe large milestone materially boosted first-half revenue but does not represent a recurring sales stream. Comparisons may weaken when similar payments are absent, making current growth and profitability less representative of ongoing product economics and increasing the importance of sustained Elfabrio sales.
PRX-115 Clinical UncertaintyHigh observed anti-drug antibody incidence and unresolved dose or regimen selection create meaningful uncertainty for PRX-115’s development path. Immunogenicity and infusion-related reaction concerns could require further optimization, affect timelines, and limit the program’s eventual commercial positioning.
Protalix News
PLX FAQ
What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was $1.52 and its highest was $3.19 in the past 12 months.
What is Protalix Biotherapeutics’s market cap?
Protalix Biotherapeutics’s market cap is $215.13M.
When is Protalix Biotherapeutics’s upcoming earnings report date?
Protalix Biotherapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 70 days.
How were Protalix Biotherapeutics’s earnings last quarter?
Protalix Biotherapeutics released its earnings results on Aug 12, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.06.
Is Protalix Biotherapeutics overvalued?
According to Wall Street analysts Protalix Biotherapeutics’s price is currently Overvalued.
Does Protalix Biotherapeutics pay dividends?
Protalix Biotherapeutics does not currently pay dividends.
What is Protalix Biotherapeutics’s EPS estimate?
Protalix Biotherapeutics’s EPS estimate is -0.05.
How many shares outstanding does Protalix Biotherapeutics have?
Protalix Biotherapeutics has 80,571,640 shares outstanding.
What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
Protalix Biotherapeutics reported an EPS of $0.05 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 7.819%.
Which hedge fund is a major shareholder of Protalix Biotherapeutics?
Currently, no hedge funds are holding shares in PLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protalix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
PLX Sentiment 100%
Sector Average 60%
Sector Average 60%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
40.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Protalix Biotherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
PLX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented several strong operational and financial positives — double-digit quarterly revenue growth, a >100% year-to-date revenue increase, meaningful Q2 net income, strong Elfabrio commercial momentum with regulatory and patent tailwinds, a solid cash position and advancing pipeline (PRX-115 with topline expected H2 2027). Offsetting risks include quarter-to-quarter revenue lumpiness and partner concentration (Chiesi), a reliance on a one-time $25M milestone in H1, increased cost of revenues and taxes, and clinical uncertainties around immunogenicity and regimen selection for PRX-115. Overall, the positives — particularly the robust revenue growth, improved profitability and cash position — outweigh the noted risks, though sustainability and immunogenicity remain items to monitor.View all PLX earnings summariesTechnical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
―
Innate Pharma
―
Ownership Overview
3.49% Insiders
2.82% Mutual Funds
1.04% Other Institutional Investors
87.38% Public Companies and
Individual Investors